Industry: Pharmaceuticals, Biotechnology
Founded in 2002, Alteris Therapeutics, Inc. (formerly Spliceomix, Inc.) is an emerging biopharmaceutical company focused on the discovery and development of therapeutics and vaccines based on alternative gene splice forms unique to cancer. The company’s first compound, ALT-110, a therapeutic vaccine against the splice variant growth factor EGFRvIII, is currently being tested in a Phase I cancer trial. Alteris also has a drug discovery program for a second proprietary target it has identified. These initial targets have been implicated in a wide variety of tumors, including breast, colon, lung, ovarian, and central nervous system ( www.alteristhera.com )
Alteris Therapeutics , Inc.
416 South 10Th Street
Philadelphia, Pennsylvania 19147
USA
Tel: (267) 972-5215
Fax: (215) 923-0567